The George Washington University is one of four US sites conducting a Phase I clinical trial to test the safety and immune responses of two mRNA vaccine antigens for HIV on 56 healthy adults. The GW Vaccine Research Unit is running one of the study sites and acting as the processing lab and biorepository. The unit has partnered with study sponsor IAVI on two other HIV vaccine-related Phase I clinical trials and conducted several other clinical vaccine trials, including one for the FDA-authorized COVID-19 vaccine. Continue reading to see more about what GW is doing for the First Human Trial of mRNA-based HIV Vaccine.
GW Participating in the First Human Trial of mRNA-based HIV Vaccine
Latest News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: